Studies from M.A Findeis and co-researchers yield new data on Alzheimer disease therapy
2007 NOV 19 -- Fresh data on Alzheimer disease are presented in the report 'The role of amyloid beta peptide 42 in Alzheimer's disease.' According to a study from the United States, "During the last 20 years, an expanding body of research has elucidated the central role of amyloid precursor protein (APP) processing and amyloid beta peptide (Abeta) production in the risk, onset, and progression of the neurodegenerative disorder Alzheimer's disease (AD), the most common form of dementia. Ongoing research is establishing a greater level of detail for our understanding of the normal functions of APP, its proteolysis products, and the mechanisms by which this processing occurs." "The importance of this processing machinery in normal cellular function, such as Notch processing, has revealed specific concerns about targeting APP processing for therapeutic purposes. Aspects of AD that are now well studied include direct and indirect genetic and other risk factors for AD, APP processing, and Abeta production. Emerging from these studies is the particular importance of the long form of Abeta, Abeta42. Elevated Abeta42 levels, as well as particularly the elevation of the ratio of Abeta42 to the shorter major form Abeta40, has been identified as important in early events in the pathogenesis of AD. The specific pathological importance of Abeta42 has drawn attention to seeking drugs that will selectively lower the levels of this peptide through reduced production or increased clearance while allowing normal protein processing to remain substantially intact. An increasing variety of compounds that modulate APP processing to reduce Abeta levels are being identified, some with Abeta42 selectivity," wrote M.A Findeis and colleagues, . The researchers concluded: "Such compounds are now reaching clinical evaluation to determine how they may be of benefit in the treatment of AD." Findeis and colleagues published the results of their research in Pharmacology and Therapeutics (The role of amyloid beta peptide 42 in Alzheimer's disease. Pharmacology and Therapeutics, 2007;116(2):266-86). For additional information, contact M.A. Findeis, Satori Pharmaceuticals Incorporated, 222 Berkeley Street, Suite 1040, Boston, MA 02116 USA.. The publisher of the journal Pharmacology and Therapeutics can be contacted at: Pergamon-Elsevier Science Ltd., the Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, England. Keywords: United States, Boston, Alzheimer Disease Therapy, Alzheimer Disease, Drugs, Pharmaceuticals, Pharmacology, Therapies, Therapy, Treatment. This article was prepared by Pain & Central Nervous System Week editors from staff and other reports. Copyright 2007, Pain & Central Nervous System Week via NewsRx.com.
|
